Neuphoria Therapeutics Inc. (NEUP): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of NEUP were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No NEUP insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NEUP short interest
Low short interest. 0.2% of NEUP shares are sold short: about 1 share in 437. Over the last 12 reports the number of shares short went down 37%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12,377 NEUP shares were sold short, 0.2% of the shares outstanding, up 92.5% from the report before. At the average daily volume of 37,998 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12,377 | 0.23% | +93% | 37,998 | 1.0 |
| Oct 15, 2026 | 6,429 | 0.12% | -68% | 16,447 | 1.0 |
| Sep 30, 2026 | 20,022 | 0.37% | -19% | 12,424 | 1.6 |
| Sep 15, 2026 | 24,713 | 0.46% | -62% | 20,204 | 1.2 |
| Aug 31, 2026 | 64,641 | 1.20% | +54% | 67,695 | 1.0 |
| Aug 14, 2026 | 42,034 | 0.78% | -36% | 28,832 | 1.5 |
| Jul 31, 2026 | 65,538 | 1.21% | +327% | 638,720 | 1.0 |
| Jul 15, 2026 | 15,334 | 0.28% | -3% | 109,747 | 1.0 |
| Jun 30, 2026 | 15,831 | 0.29% | -31% | 78,309 | 1.0 |
| Jun 15, 2026 | 23,029 | 0.43% | -37% | 76,196 | 1.0 |
| May 29, 2026 | 36,835 | 0.68% | +88% | 59,827 | 1.0 |
| May 15, 2026 | 19,598 | 0.36% | -57% | 28,089 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Neuphoria Therapeutics company events
Neuphoria Therapeutics filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (control, listing). The latest was on Oct 23, 2026.
- Oct 23, 2026AgreementThe Board of Directors of Neuphoria Therapeutics Inc., a Delaware corporation, entered into Amendment No. 1 to the Rights Agreement, dated as of October 27, 2025, by and between the Company and Computershare Trust Company, N.A., as Rights Agent (the “Original Rights Agreement,” and as amended by… Filing
- Jul 24, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report is incorporated herein by reference. Filing
- May 26, 2026AnnouncementNeuphoria Therapeutics Inc. received a revenue distribution payment of AUD $1.416M from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC) related to the Company’s licensing of the KAT6 program to Pfizer Inc. following the initiation of dosing of the first… Filing
- Jan 8, 2026AgreementAs previously announced on December 16, 2022 in a Current Report on Form 6-K filed by Bionomics Ltd. (now known as Neuphoria Therapeutics Inc., or the “Company”), the Company had appointed Spyridon “Spyros” Papapetropoulos, M.D. as President and Chief Executive Officer pursuant to the terms of that… Filing
- Dec 18, 2025ListingNotice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Filing
- Dec 17, 2025VoteReported shareholder vote results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Neuphoria Therapeutics financials
Famous investors that hold NEUP
1 of the 50 well-known investors we track reported holding NEUP in their latest 13F filing. The largest position is Ken Griffin's, worth $157K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 44,045 | $157K | 0.0% | -39% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NEUP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 5, 2026 | AdvisorShares Trust | 13G | 5.8% |
| Oct 5, 2026 | AdvisorShares Trust | 13G | 5.8% |
Questions about Neuphoria Therapeutics Inc. (NEUP) stock
Are NEUP insiders buying or selling?
No NEUP insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in NEUP?
As of Oct 30, 2026, 12,377 NEUP shares were sold short, 0.2% of the shares outstanding, up 92.5% from the report before. At the average daily volume of 37,998 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold NEUP?
1 of the 50 well-known investors we track reported NEUP in their latest 13F filing, including Ken Griffin. The largest position is worth $157K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.